15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Immunovant Inc, 6 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $30.00 to $62.00 (about 2.1x), a sign of real disagreement on valuation. The average target of $46.00 sits 17% above the current $39.26. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.67 next quarter toward $-2.75 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Moderate Buy
Strong Buy00%
Buy667%
Hold333%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to Immunovant Inc.
As of Sep, 6 of 9 firms rate IMVT a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IMVT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.67
Range $-0.77 – $-0.53 · 3 analysts · +25% YoY
Next period, 3 analysts expect Immunovant Inc to earn $-0.67 a share (range $-0.77 – $-0.53), versus $-0.54 a year earlier. Full-year consensus is $-2.84, growing to $-2.75 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $36.8M next year.
Top analysts covering Immunovant Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMVT.
#1
Yatin Suneja
Guggenheim · Rank #21
Buy
$62.00+57.9% to target
Overall win rate
53%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #125
Buy
$43.00+9.5% to target
Overall win rate
46%
+ Follow
#3
Louise Chen
Cantor Fitzgerald · Rank #183
Buy
No targeton IMVT
Overall win rate
43%
+ Follow
#4
Yasmeen Rahimi
Piper Sandler · Rank #188
Buy
$66.00+68.1% to target
Overall win rate
33%
+ Follow
#5
Douglas Tsao
HC Wainwright & Co. · Rank #248
Buy
$40.00+1.9% to target
Overall win rate
35%
+ Follow
IMVT stock forecast FAQ
What is IMVT's average 12-month price target?+
The 8 analysts with a live target average $46.00 for Immunovant Inc over the next 12 months, ranging from a $62.00 high to a $30.00 low.
Is IMVT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 9 analyst ratings, 6 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IMVT?+
The Street-high target is $62.00 (Guggenheim), and the Street-low is $30.00 (Truist Securities). The average of all 8 active targets is $46.00.
How many Wall Street analysts cover IMVT?+
9 analysts have an active rating on Immunovant Inc, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering IMVT?+
Among analysts who currently cover IMVT, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #21). Their current call is Buy with a $62.00 target.
What is Immunovant Inc's projected EPS for next quarter?+
The consensus estimate is $-0.67 per share (range $-0.77 – $-0.53) across 3 analysts. Full-year EPS is projected at $-2.84, rising to $-2.75 the following year.
How much revenue is Immunovant Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $36.8M next year.
Have analysts been upgrading or downgrading IMVT lately?+
As of Sep, 6 of 9 firms rate IMVT a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMVT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
